2015 Clinical Trials Epilepsy 
Peninsula Alternative Health
MAY 15, 2019
Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy. tetrahydrocannabinol (THC).
MMJ Recs
DECEMBER 17, 2023
Enacted in 2015, the program was designed to provide a narrow avenue for patients suffering from qualifying conditions to access low-THC cannabis under the supervision of qualified healthcare professionals. The Texas Compassionate Use Program (TCUP) represents the Lone Star State’s cautious foray into the realm of medical marijuana.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Peninsula Alternative Health
MAY 15, 2019
Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy. tetrahydrocannabinol (THC).
Canna Care Docs
DECEMBER 16, 2020
The evidence of its effectiveness is clear, as clinical trials have shown a significant reduction in pain for patients suffering with neuropathic pain from multiple sclerosis, pain from rheumatoid arthritis, cancer pain, HIV or complex regional pain syndrome, headaches and menstrual pain, among other potential uses. Chronic pain.
Cannabis Law Report
DECEMBER 28, 2021
The users of CBD products claim to have seen improvement in different medical conditions, including depression, chronic pain, insomnia, epilepsy, anxiety, etc., But things have changed after FDA eased out regulations in 2015 to carry out CBD trials. after its consumption. So, there are huge developments after that.
Cannabis Law Report
JULY 12, 2019
Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. Lancet Neurol Dec 23 2015.
Cannabis Law Report
FEBRUARY 15, 2019
The Institute of Mental Health (IMH) did a review of 500 articles between 1964 and 2015 on the effects of cannabis. There is even published research, derived from clinical trials, on the potential uses of cannabinoids to manage seizures and epilepsy, cited the ministries. It causes serious brain damage.
Expert insights. Personalized for you.
89 
Let's personalize your content